MITEM PHARMA Continues Its Mission to Protect the Interests of Patients Suffering From Rare and Lethal Diseases by Acquiring the FLISINT® Speciality from SANOFI
MITEM PHARMA, a French-based pharmaceutical company dedicated to Drugs of Major Therapeutic Interest (DMTI), is pleased to announce that it has acquired the rights to FLISINT®, an infectious disease DMTI, from SANOFI WINTHROP INDUSTRIE (Gentilly - France).
FLISINT® (fumagillin) is recognised as the only treatment capable of overcoming Enterocytozoon bieneusi microsporidia infections. This opportunistic germ develops in clinical situations of immunosuppression (e.g. AIDS or immunosuppression for organ transplantation). There is no equivalent therapeutic alternative in the world.
Since FLISINT® ceased to be marketed in 2019, the FRIPHARM® (Fabrication Recherche Innovation Pharmaceutique; Hospices Civils de Lyon) university hospital platform has been manufacturing the product as a magistral preparation, helping patients with the last remaining stock of active ingredient available from SANOFI
MITEM PHARMA has set itself the task of making available to patients and medical staff essential medicines that have been taken off the market.
At the request of the FRIPHARM® platform team, MITEM PHARMA is working to update and relaunch the active ingredient production and FLISINT® manufacturing processes.
FLISINT® currently has marketing authorization in France but is the subject of numerous requests for exceptional supplies abroad (Europe; USA; Argentina; Australia; etc.).
This acquisition underpins MITEM PHARMA's growth strategy in the DMTI sector and its determination to serve all territories affected by diseases which, while rare, are often fatal.
MITEM PHARMA, backed by the TECHLIFE CAPITAL investment fund specialising in healthcare, is bringing its expertise in DMTIs and its marketing network in over 60 countries to bear on these products.
Claude-Alain CUDENNEC and Éric THIERRY, founders of MITEM PHARMA, said: "The acquisition of FLISINT® (fumagillin) confirms MITEM PHARMA's determination to provide patients and medical teams with concrete solutions in the fight against serious diseases. MITEM PHARMA is taking over from the remarkable efforts made by FRIPHARM’s® platform to avoid a disruption in the pharmaceutical availability of fumagillin.
About MITEM PHARMA
MITEM PHARMA is a French pharmaceutical laboratory specialising inDrugs of Major Therapeutic Interest (DMTI). MITEM PHARMA's mission is to improve patients' quality of life by ensuring the availability of important medicines, which are the only treatments for severe diseases, but whose supply shortages cause public health risks. Working with partner doctors and patient associations, the company identifies these situations, and buys back, upgrades, improves or develops these major medicines to guarantee access to appropriate care. MITEM PHARMA is constantly adapting to patients, the environment and market developments to make DMTIs accessible at every stage of life, particularly in the fields of haematology, endocrinology, emergency cardiology, medical dermatology and now infectious diseases. MITEM PHARMA currently has an international presence in over 60 countries.
For more information: www.mitempharma.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250204171724/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Access Advance Announces HEVC Advance and VVC Advance Pricing through 203022.7.2025 02:00:00 CEST | Press release
Access Advance LLC (“Advance”) today announced the results of several significant decisions by the Licensors in both the HEVC Advance and VVC Advance Patent Pools. Both patent pools opted to maintain their current royalty rates and caps for Licensees who sign before December 31, 2025, and to extend an incentive that aligns the royalty caps for Advance’s Multi-Codec Bridging Agreement (“MCBA”) and the VVC Advance Patent Pool for Licensees who sign the MCBA during the same period. The result is that Licensees who join the HEVC Advance program, gaining access to more than 27,000 patents, on or before December 31, 2025, can lock in current rates and caps through 2030. This protection applies both to ongoing royalty obligations and calculation of royalties due for past sales. Additionally, both current and new HEVC Advance Licensees who join the VVC Advance Patent Pool and execute the MCBA by December 31, 2025, will enjoy MCBA royalty caps that match the royalty caps for the VVC Advance pro
Andersen Consulting tilføjer ekspertise inden for markedsadgang med Prime Action i Brasilien22.7.2025 00:50:00 CEST | Pressemeddelelse
Andersen Consulting styrker sin kapacitet i Latinamerika med tilføjelsen af samarbejdsfirmaet Prime Action Consulting, et firma med speciale i markedsadgangsstrategi og channel management inden for bil-, landbrugs-, bank-, medicinal- og telekommunikationssektoren. Prime Action leverer komplette kommercielle konsulenttjenester for at hjælpe organisationer med at optimere deres go-to-market-strategier og forbedre resultaterne på tværs af salgs- og distributionskanaler. Firmaets tilbud omfatter markedsadgangsstrategi, intelligent channel management, udarbejdelse af handels- og distributionspolitik, kanaludviklingstjenester og uddannelse, som alle er designet til at skabe effektivitet og kundetilpasning gennem strukturerede processer, standarder og målrettet eksekvering. Prime Action arbejder med førende virksomheder i hele Latinamerika og følger ikke blot kunderne fra planlægning til implementering, men også efter implementeringen, hvor de tilbyder relevant uddannelse og evaluering for at
MayMaan Launches Engine Integration Program to Accelerate Clean Combustion Deployment and Market Adoption21.7.2025 19:34:00 CEST | Press release
Company unveils a comprehensive framework to empower manufacturers, OEMs, distributors and service partners with drop-in clean combustion solutions MayMaan, a scale-up innovator, transforming combustion technology, is announcing a robust and scalable partnership model to support the transition to more efficient power systems across global industries whilst cutting harmful emissions such as NOx and SOx to levels that are practically immeasurable. At the heart of MayMaan’s offering is its proprietary AquaStroke® technology, which runs on a revolutionary 70% water and 30% ethanol fuel blend. This patented system delivers high torque and reliability while dramatically reducing emissions—offering a compelling alternative to diesel engines and electrification overhauls. “Our technology is more than a breakthrough—it’s a platform designed to help others succeed,” said Doron Shmueli, Founder and CEO at MayMaan. “From manufacturers to distributors, we provide a full solution—ready to integrate,
Armis Named a Leader in Unified Vulnerability Management Solutions, Q3 2025 Evaluation21.7.2025 17:25:00 CEST | Press release
Company achieved the highest score of all providers for its Current Offering Armis, the cyber exposure management & security company, today announced that it has been named a Leader in The Forrester Wave™: Unified Vulnerability Management Solutions, Q3 2025. In this Forrester Wave™, Armis is ranked a Leader and achieved the highest score in the Current Offering category. According to the report, “Armis’ strategy is grounded in proactive security principles… Armis is an excellent fit for either beginner organizations starting their proactive security journey or mature organizations that need leading vulnerability response capabilities.” “I believe Armis stood out as a Leader because Armis CentrixTM is different – it’s a platform built to help organizations reduce cyber risk, not just report on it,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “We are redefining what security should look like in a connected world, helping organizations move from passive defense to proactive control
DevvStream Completes $10M Initial Funding to Launch $300M Asset-Backed Digital Infrastructure and Sustainability Strategy21.7.2025 17:00:00 CEST | Press release
DevvStream Corp. (Nasdaq: DEVS) (“DevvStream” or the “Company”), a leading carbon management firm specializing in the development, investment, and sale of environmental assets, today announced that it has entered into a securities purchase agreement for the issuance of up to (US)$300 million in senior secured convertible notes (“Senior Notes”), advancing its strategic initiative to build a blockchain-based treasury and launch a tokenization platform for sustainability-linked infrastructure. The securities purchase agreement provides for the issuance of up to (US)$300 million in Senior Notes with Helena Partners, which issuances will be funded in multiple tranches. An initial funding of (US)$10 million was completed on July 18, 2025. Key Highlights: Under the agreement, DevvStream will allocate 75% of the net proceeds (70% of the initial tranche) toward the purchase of liquid digital assets that offer 24/7 liquidity, serve as non-correlated stores of value, and may be used as collateral
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom